These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Response to Wiwanitkit et al. comment on the report: 'A randomised trial investigating the safety and efficacy of influenza vaccination in patients with ANCA-associated vasculitis'. Jeffs L Nephrology (Carlton); 2015 Aug; 20(8):584. PubMed ID: 26194987 [No Abstract] [Full Text] [Related]
4. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948 [TBL] [Abstract][Full Text] [Related]
5. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Holvast A; Stegeman CA; Benne CA; Huckriede A; Wilschut JC; Palache AM; Kallenberg CG; Bijl M Ann Rheum Dis; 2009 Jun; 68(6):873-8. PubMed ID: 18625625 [TBL] [Abstract][Full Text] [Related]
6. Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus. Rasoolinejad M; Jafari S; Montazeri M; Mohseni M; Foroughi M; Moradmand Badie B; Saatian M; Marashi SM; Mokhtari Azad T Acta Med Iran; 2013 Apr; 51(3):148-52. PubMed ID: 23605597 [TBL] [Abstract][Full Text] [Related]
7. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Strijbos E; Tannemaat MR; Alleman I; de Meel RHP; Bakker JA; van Beek R; Kroon FP; Rimmelzwaan GF; Verschuuren JJGM Vaccine; 2019 Feb; 37(7):919-925. PubMed ID: 30660402 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476 [TBL] [Abstract][Full Text] [Related]
9. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe. Pérez-Romero P; Bulnes-Ramos A; Torre-Cisneros J; Gavaldá J; Aydillo TA; Moreno A; Montejo M; Fariñas MC; Carratalá J; Muñoz P; Blanes M; Fortún J; Suárez-Benjumea A; López-Medrano F; Barranco JL; Peghin M; Roca C; Lara R; Cordero E; ; Clin Microbiol Infect; 2015 Nov; 21(11):1040.e11-8. PubMed ID: 26232537 [TBL] [Abstract][Full Text] [Related]
10. Antineutrophil cytoplasmic antibody vasculitis associated with influenza vaccination. Duggal T; Segal P; Shah M; Carter-Monroe N; Manoharan P; Geetha D Am J Nephrol; 2013; 38(2):174-8. PubMed ID: 23941822 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. Anar C; Bicmen C; Yapicioglu S; Unsal I; Halilcolar H; Yilmaz U New Microbiol; 2010 Apr; 33(2):117-27. PubMed ID: 20518273 [TBL] [Abstract][Full Text] [Related]
12. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949 [TBL] [Abstract][Full Text] [Related]
13. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. deBruyn J; Fonseca K; Ghosh S; Panaccione R; Gasia MF; Ueno A; Kaplan GG; Seow CH; Wrobel I Inflamm Bowel Dis; 2016 Mar; 22(3):638-47. PubMed ID: 26595551 [TBL] [Abstract][Full Text] [Related]
15. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? Skowronski DM; Tweed SA; De Serres G J Infect Dis; 2008 Feb; 197(4):490-502. PubMed ID: 18275271 [TBL] [Abstract][Full Text] [Related]
16. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Madhi SA; Maskew M; Koen A; Kuwanda L; Besselaar TG; Naidoo D; Cohen C; Valette M; Cutland CL; Sanne I Clin Infect Dis; 2011 Jan; 52(1):128-37. PubMed ID: 21148531 [TBL] [Abstract][Full Text] [Related]
17. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444 [TBL] [Abstract][Full Text] [Related]
18. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951 [TBL] [Abstract][Full Text] [Related]
19. Debate on annual influenza vaccination in healthcare workers for the same subtype under the vaccine shortage. Song JY; Ha SH; Kee SY; Jeong HW; Cheong HJ; Kim WJ J Clin Virol; 2007 Feb; 38(2):149-52. PubMed ID: 17196876 [TBL] [Abstract][Full Text] [Related]